TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31968207

Group type: EXPERIMENTAL
Intervention: Carrier phrase present (VA-1 speaker)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Carrier phrase absent (VA-1 speaker)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Carrier phrase present (VA-2 speaker)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Carrier phrase absent (VA-2 speaker)
Number of subjects: 72
Study: 31351085

Group type: EXPERIMENTAL
Intervention: BoNT & occupational therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: BoNT therapy alone
Number of subjects: 12
Study: 28053265

Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 273

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 273
Study: 25793765

Group type: EXPERIMENTAL
Intervention: Insulin regimen
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ADC values in the clinically relevant penumbra
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Poor prognosis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: No arterial recanalization
Number of subjects: 99
Study: 23672353

Group type: EXPERIMENTAL
Intervention: Qishen Yiqi dripping pills (QSYQ)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study: 21872452

Group type: EXPERIMENTAL
Intervention: Catecholamine depletion (CD) using oral alpha‐methyl‐para‐tyrosine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Catecholamine depletion (CD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 19141997

Group type: EXPERIMENTAL
Intervention: Paricalcitol treatment under DCa = 3.5 mEq/l
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paricalcitol treatment under DCa = 3.0 mEq/l
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paricalcitol treatment under DCa = 2.5 mEq/l
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (DCa not specified)
Number of subjects: 12
Study: 17572962

Group type: EXPERIMENTAL
Intervention: Active Living Every Day (ALED) program
Number of subjects: 30
Study: 15276192

Group type: EXPERIMENTAL
Intervention: Prognostic scale based on liver and lung metastases, functional performance status, weight loss, edema, cognitive impairment, tiredness, and ascites
Number of subjects: 540
Study: 11372675

Group type: EXPERIMENTAL
Intervention: Certoparin (6.0 kDa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) (13.0 kDa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin (4.5 kDa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium molecular weight heparin (HF) (10.5 kDa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparins (general)
Number of subjects: 0
Study: 9505918

Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8159637

Group type: EXPERIMENTAL
Intervention: 12 IU/ml preparation of growth hormone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 56 IU/ml preparation of growth hormone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Both preparations
Number of subjects: 9
Study: 3346087

Group type: EXPERIMENTAL
Intervention: Noise exposure (60, 85, or 90 dB (A) white noise) with task demand (task presence)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Noise exposure (60, 85, or 90 dB (A) white noise) with task absence
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Task demand (mental arithmetic for 3 min and abacus arithmetic for 30 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no task demand)
Number of subjects: 40
Study: 31206934

Group type: EXPERIMENTAL
Intervention: SVN‐2B peptide vaccination
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no SVN‐2B peptide vaccination)
Number of subjects: 13
Study: 27444642

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 162

Group type: COMPARATOR
Intervention: Sham Acupressure
Number of subjects: 162

Group type: COMPARATOR
Intervention: Routine Care
Number of subjects: 162
Study: 26683546

Group type: COMPARATOR
Intervention: Emphasis terms in warning directives (e.g., 'urgent', 'recommended')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emphasis terms in warning directives (e.g., 'important', 'compulsory')
Number of subjects: 0
Study: 23721957

Group type: EXPERIMENTAL
Intervention: Screening arm (biennial PSA testing)
Number of subjects: 13423

Group type: COMPARATOR
Intervention: Control arm (not invited to screening)
Number of subjects: 13423

Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 13423

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 13423
Study: 21204681

Group type: EXPERIMENTAL
Intervention: 5‐4‐3‐2‐1 Go! counseling
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Parental exposure to messaging at children's school events
Number of subjects: 524
Study: 19317164

Group type: EXPERIMENTAL
Intervention: Dannang Recipe No. 2 (DNR2) - one dose per day starting from the previous night of operation, composed of various herbal ingredients.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Ceftizoxime sodium 2.0 g or Levofloxacin 200 mg via intravenous dripping once 0.5 h before operation and 1-3 days after operation.
Number of subjects: 360
Study: 17956456

Group type: EXPERIMENTAL
Intervention: Aerobic capacity (measured by Chester Step Test)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Handgrip strength
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 141
Study: 14988344

Group type: EXPERIMENTAL
Intervention: Alcohol group (consumed alcohol)
Number of subjects: 351

Group type: COMPARATOR
Intervention: No alcohol group (did not consume alcohol)
Number of subjects: 351
Study: 11707687

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg and Enalapril 10 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Nitrendipine 5 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Combination of nitrendipine and enalapril
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study: 9009805

Group type: EXPERIMENTAL
Intervention: Airpuffs to the left or right temple while viewing unpleasant pictures
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Airpuffs to the left or right temple while viewing pleasant pictures
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Airpuffs to the left or right temple while viewing neutral pictures
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison of left vs right side of probe presentation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison of left vs right side of response
Number of subjects: 96
Study: 7963143

Group type: EXPERIMENTAL
Intervention: Beta-carotene administration without a meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene administration with meals (varied calories and fat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene administration with high dietary fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene administration with high caloric content
Number of subjects: 0
Study: 2961357

Group type: EXPERIMENTAL
Intervention: Clodronate 400 mg/d
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg/d
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Etidronate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Salmon calcitonin
Number of subjects: 14
Study: 29417590

Group type: EXPERIMENTAL
Intervention: Physical IPV during pregnancy
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Sexual IPV during pregnancy
Number of subjects: 400
Study: 28153051

Group type: EXPERIMENTAL
Intervention: Blinded digital image assessment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Unblinded assessment
Number of subjects: 108
Study: 25775441

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 135
Study: 23452680

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 20071099

Group type: EXPERIMENTAL
Intervention: Attention deficit symptoms
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hyperactivity symptoms
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Baseline attention deficit symptoms
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Baseline hyperactivity symptoms
Number of subjects: 75
Study: 18261100

Group type: EXPERIMENTAL
Intervention: Intralesional 5-fluorouracil, lidocaine, and epinephrine (5-FU+LE) - 4 mL of 50 mg/mL 5-fluorouracil and 1 mL of a mixture of 20 mg/mL [2%] lidocaine and 0.0125 mg/mL epinephrine, administered up to four times at weekly intervals.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (intralesional normal saline)
Number of subjects: 34
Study: 16813531

Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day, orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14597516

Group type: EXPERIMENTAL
Intervention: Topical aminocaproic acid (Caprogel)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 51
Study: 10892526

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) intervention for 10 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Wait-list control group for 10 weeks
Number of subjects: 59
Study: 8635109

Group type: EXPERIMENTAL
Intervention: CT + RT (Cisplatin 100mg/m2 on day 1, 5-fluorouracil 1000 mg/m2 from day 1 to 5, followed by RT)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: CT + RT
Number of subjects: 94

Group type: COMPARATOR
Intervention: RT (64.8 Gy in 1.8 Gy fractions)
Number of subjects: 94

Group type: COMPARATOR
Intervention: RT
Number of subjects: 94
Study: 1429349

Group type: EXPERIMENTAL
Intervention: Subliminal audiotapes from a manufacturer
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo tapes
Number of subjects: 3

Group type: COMPARATOR
Intervention: No tapes
Number of subjects: 3
Study: 3914174

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha‐2C monotherapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: VMCP‐polychemotherapy
Number of subjects: 42
Study: 31838879

Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive behavioral exercise and dietary intervention (EX+D)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard-of-care (SC) treatment
Number of subjects: 32
Study: 30024539

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (normal skin)
Number of subjects: 27
Study: 26513278

Group type: EXPERIMENTAL
Intervention: Prebiotics (short‐chain galacto‐oligosaccharids/long‐chain fructo‐oligosacarids)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 50
Study: 25351119

Group type: EXPERIMENTAL
Intervention: Conventional nursing and peer education
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 240
Study: 22770649

Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg/day for 1 week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20413968

Group type: EXPERIMENTAL
Intervention: Flour fortification with iron
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (non-fortified flour)
Number of subjects: 200
Study: 17493108

Group type: EXPERIMENTAL
Intervention: Nicotine lozenges
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study: 16221950

Group type: EXPERIMENTAL
Intervention: Bee sting therapy (live bees, up to 20, administered three times per week for 24 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bee sting therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 26
Study: 12030735

Group type: EXPERIMENTAL
Intervention: Intravenous steroids and aerosol bronchodilators (40 mg methylprednisolone IV, decreasing to 20 mg after 10 days, then 4 mg x 4 days; 10 mg salbutamol and 1 mg ipratropiumbromide aerosol therapy)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oral steroids and MDI bronchodilators (32 mg methylprednisolone orally for 1 week, then 24 mg x day(‐1) for 4 days, decreasing to 4 mg x week(‐1); 1.6 mg fenoterol and 640 microg ipratropiumbromide MDI with a spacer)
Number of subjects: 37
Study: 9888878

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 7741534

Group type: EXPERIMENTAL
Intervention: Intravenous enterostatin (D3800) 4 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous enterostatin (D3800) 16 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1675527

Group type: EXPERIMENTAL
Intervention: Zinc oxide with gum rosin vehicle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc oxide with hydrocolloid vehicle
Number of subjects: 0
Study: 7040229

Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 2529

Group type: COMPARATOR
Intervention: No reserpine
Number of subjects: 2529
Study: 31860466

Group type: EXPERIMENTAL
Intervention: Protection-motivation theory constructs
Number of subjects: 380
Study: 29536205

Group type: EXPERIMENTAL
Intervention: 8 mg of dexamethasone orally 1 hour before the procedure
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4 mg dexamethasone orally 1 hour before and 24 hours after the procedure
Number of subjects: 50
Study: 27641781

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 52
Study: 24699466

Group type: EXPERIMENTAL
Intervention: Investigational vaccine formulations (10 or 30μg each of dPly and PhtD, alone or in combination with PHiD-CV)
Number of subjects: 257

Group type: COMPARATOR
Intervention: PHiD-CV (licensed vaccine)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 30 μg dPly/PhtD with PHiD-CV-conjugates
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: All pneumococcal protein-containing formulations
Number of subjects: 257
Study: 22432716

Group type: EXPERIMENTAL
Intervention: Neurofunctional treatment (NFT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (after crossover)
Number of subjects: 23
Study: 19280178

Group type: EXPERIMENTAL
Intervention: Early active range of motion rehabilitation using a bicycle ergometer equipped with an adjustable pedal arm, 6 sessions over 2 weeks post-operatively under supervision
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 17225879

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 15204674

Group type: EXPERIMENTAL
Intervention: Buprenorphine maintenance treatment
Number of subjects: 139

Group type: COMPARATOR
Intervention: Methadone maintenance treatment
Number of subjects: 139
Study: 12426274

Group type: EXPERIMENTAL
Intervention: Informed administration of the Chronic Respiratory Questionnaire (CRQ)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Informed administration of the St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Blind administration of the CRQ
Number of subjects: 85

Group type: COMPARATOR
Intervention: Blind administration of the SGRQ
Number of subjects: 85
Study: 10458359

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control (radical prostatectomy alone)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Prostatic intraepithelial neoplasia
Number of subjects: 278

Group type: COMPARATOR
Intervention: No prostatic intraepithelial neoplasia
Number of subjects: 278
Study: 7614504

Group type: EXPERIMENTAL
Intervention: cilazapril
Number of subjects: 257

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 257
Study: 2699071

Group type: EXPERIMENTAL
Intervention: Definitive irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cystectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study: 795610

Group type: EXPERIMENTAL
Intervention: 250 mg naproxen twice daily
Number of subjects: 191

Group type: COMPARATOR
Intervention: 50 mg indomethacin twice daily
Number of subjects: 191
Study: 30882524

Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural boluses (6-mL every 45 minutes of 0.1% ropivacaine with 2 µg/mL fentanyl)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Continuous epidural infusion (8 mL/h of 0.1% ropivacaine with 2 µg/mL fentanyl)
Number of subjects: 120
Study: 29947142

Group type: EXPERIMENTAL
Intervention: Cognitive games group (experimental group) - card and board games training executive functions, 30-min training session twice a week for six weeks.
Number of subjects: 118

Group type: COMPARATOR
Intervention: Wait-list control group (regular school lessons).
Number of subjects: 118
Study: 28513426

Group type: EXPERIMENTAL
Intervention: Test product (pregabalin 150-mg capsule)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference product (pregabalin 150-mg capsule)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Test and Reference products (pregabalin 150-mg capsule)
Number of subjects: 20
Study: 24737669

Group type: EXPERIMENTAL
Intervention: Nurse-delivered intervention
Number of subjects: 782

Group type: COMPARATOR
Intervention: Coach intervention
Number of subjects: 782

Group type: COMPARATOR
Intervention: Automated voice response system
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Depressive symptomatology
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 782
Study: 23453292

Group type: EXPERIMENTAL
Intervention: Scientific Hip Prosthesis (SHP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Omnifit
Number of subjects: 75
Study: 22094540

Group type: EXPERIMENTAL
Intervention: Docetaxel/gemcitabine (arm A: docetaxel 75 mg/m(2) on day 1, gemcitabine 1,000 mg/m(2) on days 1 and 8)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Docetaxel/capecitabine (arm B: docetaxel 75 mg/m(2) on day 1, capecitabine 1,250 mg/m(2) twice daily on days 1-14)
Number of subjects: 72
Study: 18443023

Group type: EXPERIMENTAL
Intervention: HBBS-treated groups
Number of subjects: 3711

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 3711
Study: 16826097

Group type: EXPERIMENTAL
Intervention: Fluoride-containing acrylic bone cement
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional acrylic bone cement
Number of subjects: 90
Study: 12877614

Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (EVBT) with high-dose-rate (192)Ir irradiation (12 Gy for a reference vessel radius of 3 mm and a 2-mm reference depth)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Angioplasty alone (control)
Number of subjects: 100
Study: 11774060

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (500 or 1000 mg of Vitamin C and 500 or 1000 IU of Vitamin E)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9580355

Group type: EXPERIMENTAL
Intervention: Early retirement due to physical or accident purpose
Number of subjects: 78

Group type: COMPARATOR
Intervention: Early retirement (general)
Number of subjects: 78
Study: 8126620

Group type: EXPERIMENTAL
Intervention: High-protein diet (5 g/kg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard-protein diet (2.5 g/kg/day)
Number of subjects: 29
Study: 2742633

Group type: EXPERIMENTAL
Intervention: Observation of the Brazelton neonatal behavioral assessment scale on 2- to 3-day-old infants.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 44
Study: 239281

Group type: EXPERIMENTAL
Intervention: Low dose of alcohol in smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of low dose of alcohol and tobacco in smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate dose of alcohol in nonsmokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking dose of nicotine with low levels of alcohol in smokers
Number of subjects: 0
Study: 31545510

Group type: EXPERIMENTAL
Intervention: Mannitol in cardiopulmonary bypass prime solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31439215

Group type: EXPERIMENTAL
Intervention: Ezetimibe added to statin therapy
Number of subjects: 7195
Study: 26887354

Group type: EXPERIMENTAL
Intervention: HIIT85 (submaximal interval training at 85% maximal aerobic power)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HIIT115 (supramaximal interval training at 115% maximal aerobic power)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HIIT85 (submaximal interval training)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HIIT115 (supramaximal interval training)
Number of subjects: 17
Study: 26261033

Group type: EXPERIMENTAL
Intervention: SPC5001 (5 mg kg(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SPC5001
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23228252

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) apical plugs
Number of subjects: 221
Study: 21679324

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 12 weeks of alpine ski training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both IG and CG
Number of subjects: 42
Study: 19339137

Group type: EXPERIMENTAL
Intervention: Training in a Moderate Drinking protocol via an Internet-based program (www.moderatedrinking.com) and use of the online resources of Moderation Management (MM; www.moderation.org)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Use of the online resources of MM alone
Number of subjects: 84
Study: 16897149

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0